The Subject Expert Committee (SEC) under India's drug regulator has given a nod for COVID-19 vaccine Covaxin trials in children in the 2-18 age group.
Subject Expert Committee (SEC) has given a recommendation to DCGI (Drugs Controller General of India) for the use of BharatBiotech's Covaxin for 2-18 year olds: Official sources
— ANI (@ANI) October 12, 2021
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


